Ipsen

News

Trial backs use of Cabometyx, Tecentriq in prostate cancer

Ipsen and Exelixis could expand the use of blockbuster oncology drug Cabometyx into prostate cancer, based on data from a phase 3 study – and help bring a cancer immunothe

News

Ipsen drug is first therapy for rare bone disease FOP in US

With FDA approval, Ipsen's marathon effort to bring palovarotene to market for the rare disease fibrodysplasia ossificans progressiva (FOP) has finally crossed the finish

News

Ipsen gets second FDA approval for itch drug Bylvay

It’s a case of so far, so good for Ipsen with its recent acquisition of Albireo, after the main asset in the deal – Bylvay – secured FDA approval for its second rare disea

R&D

Health Innovators – Jennifer Schranz

In the rare and ultra-rare disease space, the paucity of both data and patients makes everything about research and development more complicated.

News

NICE rejects Ipsen’s Cabometyx in thyroid cancer

Ipsen’s Cabometyx should not be used by the NHS for patients with differentiated thyroid cancer who have either not responded to or are ineligible for radioactive iodine t

News